Phase 3 Clinical Trials With Primary Completion Dates in September 2023

This is a list of Phase 3 trials with primary completion dates in September 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
AEZS Aeterna Zentaris Inc. 2023-09-01 Phase 3 NCT04786873 A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is
ARQT Arcutis Biotherapeutics, Inc. 2023-09-01 Phase 3 NCT04286607 Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
CYTK Cytokinetics, Incorporated 2023-09-01 Phase 3 NCT05186818 CY 6031 Study Will Evaluate the Effects of Treatment With Aficamten (CK-3773274) Over a 24-week Period on Cardiopulmonary Exercise Capacity and Health Status in Patients With Symptomatic oHCM
FSPKF Fisher & Paykel Healthcare Corporation Limited 2023-09-01 Phase 3 NCT05505279 Ventilatory Effects of THRIVE During EBUS
IMGN ImmunoGen, Inc. 2023-09-01 Phase 3 NCT04209855 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MMSI Merit Medical Systems, Inc. 2023-09-01 Phase 3 NCT03960008 Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant
NVCR NovoCure Limited 2023-09-01 Phase 3 NCT02973789 Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
NVCR NovoCure Limited 2023-09-01 Phase 3 NCT03940196 Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)
XENE Xenon Pharmaceuticals Inc. 2023-09-01 Phase 3 NCT04912856 An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
ZYNE Zynerba Pharmaceuticals, Inc. 2023-09-01 Phase 3 NCT04977986 Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome